NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Erasca, Inc. (ERAS) Stock Analysis

Erasca, Inc. (ERAS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ERAS

$16.19

−$0.07 (−0.43%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ERAS with… →

ERAS Key Statistics

As of Sep 4, 2026
Trading
Open
$16.04
Previous Close
$16.26
Day's Range
15.77–16.40
52-Week Range
1.53–24.28
Volume
2.06M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.65
Valuation
Market Cap
$5.66B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$124.55M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
349.76M
1-Year Return
+993.92%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
4.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ERAS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+335.22%
2025+48.21%
2024+17.84%
2023−50.58%
2022−72.34%
2021 (partial year)−10.61%

As of September 4, 2026.

ERAS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$124.55M—
2024$0.00−$161.65M—
2023$0.00−$125.04M—
2022$0.00−$242.81M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$131.41M−$124.55M—
2024$0.00—−$157.09M−$161.65M—
2023$0.00—−$141.53M−$125.04M—
2022$0.00—−$145.45M−$242.81M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ERAS Valuation vs Biotechnology Median

Median of 656 stocks
MetricERASBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Erasca, Inc. (ERAS) is capitalised at $5.66B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 103 employees.

ERAS last closed at $16.19 on September 4, 2026. That is −$0.07 (−0.43%) against the previous close. Over the past 52 weeks the price has ranged from $1.53 to $24.28. The latest close sits 961.64% above that 52-week low.

Financial Health

In fiscal 2025, Erasca, Inc. reported revenue of $0.00. The same year closed with a net loss of $124.55M. The reported profit margin is 0%. Trailing earnings per share are −0.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +993.92%. Across 5 years the annualized return works out at −7.46%. Beta against the wider market is reported at 0.65. Daily returns over the trailing 5 years annualize to a volatility of 83.32%.

Growth & Income

No dividend is on file for ERAS.

2026 is still running; the price is +335.22% year to date. The strongest complete calendar year on file is 2025 at +48.21%; the weakest is 2022 at −72.34%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Erasca, Inc. (ERAS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Erasca, Inc. ERAS $5.66B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Erasca, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit website →